Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC
在PD-L1未选择的转移性非小细胞肺癌患者中,斯帕塔利珠单抗联合铂类双药化疗,可联合或不联合卡那单抗。
期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-024-12841-2
Santoro, Armando; Pilar, Garrido; Tan, Daniel S W; Zugazagoitia, Jon; Shepherd, Frances A; Bearz, Alessandra; Barlesi, Fabrice; Kim, Tae Min; Overbeck, Tobias R; Felip, Enriqueta; Cai, Can; Eddy, Simantini; McCulloch, Tracey; Schaefer, Eric S